

October 19, 2009
Gothenburg, Sweden

New reporting date, Vitrolife's interim report and invitation to conference call on the interim report

Due to the merger between Vitrolife's largest shareholder, Skanditek, and Bure, Vitrolife will change reporting date for the interim report January-September to Monday October 26, 2009.

Invitation to attend Vitrolife's conference call regarding presentation of the interim report for the period January-September 2009. The presentation will be held in English.

Time: Tuesday, October 27, 2009 at 10 a.m. CET.

Registration can be done in advance under the following link:

<https://eventreg1.conferencing.com/webportal3/reg.html?Acc=830257&Conf=169038>

or shortly before time of the conference starts on:

Telephone number: +46 8 505 201 10 (Please quote 848837)

Conference name: Vitrolife

Vitrolife participants:

Magnus Nilsson, CEO

Eva Nilsagård, CFO

The press release for Vitrolife's interim report will be released at 3.00 p.m. CET on October 26.

Before the conference call, slides will be available at the company web page, www.vitrolife.com, under the section Investors/News.

A recorded version of the presentation will be available for seven days on number +46 8 505 203 33, access code 848837.

Gothenburg
October 19, 2009

Magnus Nilsson
CEO

Queries should be addressed to:

Eva Nilsagård, CFO, phone +46 31 721 80 13

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 160 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Monday October 19, 2009 at 09.00 am.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.